Details of the Drug Combinations

General Information of This Drug (ID: DM2R68E)

• Drug Name: Ramipril (DM2R68E)
• Synonyms: Acovil; Altace; Carasel; Cardace; Delix; Hypren; Hytren; Lostapres; Naprix; Pramace; Quark; Ramace; Ramiprilum; Triatec; Tritace; Vesdil; Zabien; Almirall Brand of Ramipril; Astra Brand of Ramipril; AstraZeneca Brand of Ramipril; Aventis Brand of Ramipril; Aventis Pharma Brand of Ramipril; Hoechst Brand of Ramipril; Monarch Brand of Ramipril; Promed Brand of Ramipril; Ramiprilum [Latin]; HOE 498; HOE498; Altace (TN); Hoe-498; Pramace (discontinued); Tritace (TN); Ramipril (USP/INN); Ramipril [USAN:INN:BAN]; Ramipro, Tritace, Altace, Prilace, Ramipril; N-(1S-carboethoxy-3-phenylpropyl)-S-alanyl-cis,endo-2-azabicyclo[3.3.0]octane-3S-carboxylic Acid; [2s,3as,6as]-1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopen; [2S,3aS,6aS]-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2 S ,3 aS,6 aS)-1[(S)-N-[(S)-1-Carboxy-3-phenylpropyl] alanyl] octahydrocyclopenta [ b ]pyrrole-2-carboxylic acid, 1-ethyl ester; (2S,3aS,6aS)-1-((S)-2-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl) octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid, 1-ethyl ester; (2S,3aS,6aS)-1-((S)-N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrol-2-carbonsaeure; (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-[(2S)-2-{[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (non-preferred name); (2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid; (2s,3as,6as)-1((s)-n-((s)-1-carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic; (2s,3as,6as)-1-((s)-2-((s)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)-octahydrocyclopenta[b]p; (2s,3as,6as)-1-[(s)-2-((s)-1-ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-cyclopenta[b]

Indication

Acute heart failure; ICD 11: BD10-BD13; Status: Approved [1]; Chronic heart failure; ICD 11: BD1Z; Status: Approved [2]; Congestive heart failure; ICD 11: BD10; Status: Approved [3]; Coronavirus Disease 2019 (COVID-19); ICD 11: 1D6Y; Status: Phase 2 [4]; Stroke; ICD 11: 8B20; Status: Investigative [2]

• Therapeutic Class: Antihypertensive Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Ramipril + Idarubicin	DC0DODJ	Idarubicin	Glioblastoma? (Cell Line: T98G)	[5]

9 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Aliskiren + Ramipril	DCE62MP	Aliskiren	Heart Failure	[6]
Allopurinol + Ramipril	DC59KO3	Allopurinol	Diabetes	[7]
Amlodipine + Ramipril	DC4ONE7	Amlodipine	Hypertension With Metabolic Syndrome	[8]
Clopidogrel + Ramipril	DCFN2J8	Clopidogrel	Diabetes Type 2	[9]
Amlodipine + Ramipril	DCF4LLD	Amlodipine	Hypertension	[10]
Bisoprolol + Ramipril	DCSN6WE	Bisoprolol	Breast Cancer	[11]
Amlodipine + Ramipril	DCOOXCJ	Amlodipine	Essential Hypertension	[12]
Amlodipine + Ramipril	DCCHOBT	Amlodipine	Hypertension	[13]
Nebivolol + Ramipril	DCZC0T9	Nebivolol	Hypertension	[14]

References

• [1] FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 202392.
• [2] Ramipril FDA Label
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6339).
• [4] ClinicalTrials.gov (NCT04366050) Ramipril for the Treatment of COVID-19. U.S. National Institutes of Health.
• [5] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [6] ClinicalTrials.gov (NCT00923156) Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure
• [7] ClinicalTrials.gov (NCT01052272) Impact of Diabetes on Left Ventricular Remodeling
• [8] ClinicalTrials.gov (NCT00542269) Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome
• [9] ClinicalTrials.gov (NCT01743014) Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy
• [10] ClinicalTrials.gov (NCT00368277) A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly
• [11] ClinicalTrials.gov (NCT02236806) Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab
• [12] ClinicalTrials.gov (NCT01180413) Intensive Vasodilator Therapy in Patients With Essential Hypertension
• [13] ClinicalTrials.gov (NCT01922141) Aliskiren Study of Safety and Efficacy in Senior Hypertensives
• [14] ClinicalTrials.gov (NCT06104423) Open-label, Multicenter, multinAtionaL, inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients